Head-to-head evidence
AND017 vs SSS17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
AND017
Developed by Kind Pharmaceuticals
NCT05265325 · Phase 2 · completed
The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2026 · NCT07494409 (registry estimate)
SSS17
Developed by Shenyang Sunshine Pharmaceutical
NCT07014631 · Phase 2 · completed
The study randomized 86 participants to SSS17 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in hemoglobin, a laboratory surrogate measure, and the comparison has not been reported, so no conclusion can yet be drawn about whether the endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · SSS17's landscape